Literature DB >> 24441042

Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-α protein levels and activity.

M J Bolt1, F Stossi1, A M Callison1, M G Mancini1, R Dandekar1, M A Mancini1.   

Abstract

Estrogen receptor-α (ERα) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ERα-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ERα protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ERα protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ERα target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ERα levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERα protein levels and transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24441042      PMCID: PMC4871123          DOI: 10.1038/onc.2013.550

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

1.  Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators.

Authors:  Aliesha González-Arenas; Valeria Hansberg-Pastor; Olivia Tania Hernández-Hernández; Tania Karina González-García; Joshua Henderson-Villalpando; Diana Lemus-Hernández; Aglaé Cruz-Barrios; Mariana Rivas-Suárez; Ignacio Camacho-Arroyo
Journal:  Biochim Biophys Acta       Date:  2011-11-21

2.  Estrogen-receptor-alpha exchange and chromatin dynamics are ligand- and domain-dependent.

Authors:  Z Dave Sharp; Maureen G Mancini; Cruz A Hinojos; Fangyan Dai; Valeria Berno; Adam T Szafran; Kelly P Smith; Tanmay P Lele; Tanmay T Lele; Donald E Ingber; Michael A Mancini
Journal:  J Cell Sci       Date:  2006-09-12       Impact factor: 5.285

3.  High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.

Authors:  F J Ashcroft; J Y Newberg; E D Jones; I Mikic; M A Mancini
Journal:  Gene       Date:  2011-01-20       Impact factor: 3.688

4.  A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

Authors:  Emily M Fox; Todd W Miller; Justin M Balko; Maria G Kuba; Violeta Sánchez; R Adam Smith; Shuying Liu; Ana María González-Angulo; Gordon B Mills; Fei Ye; Yu Shyr; H Charles Manning; Elizabeth Buck; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-09-09       Impact factor: 12.701

5.  Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.

Authors:  Xinghua Long; Kenneth P Nephew
Journal:  J Biol Chem       Date:  2006-02-03       Impact factor: 5.157

6.  EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response.

Authors:  Michelle J Henderson; Amanda J Russell; Samantha Hird; Marcia Muñoz; Jennifer L Clancy; Gillian M Lehrbach; Sophina T Calanni; David A Jans; Robert L Sutherland; Colin K W Watts
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

7.  MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.

Authors:  Xiaoting Zhang; Andrew Krutchinsky; Aya Fukuda; Wei Chen; Soichiro Yamamura; Brian T Chait; Robert G Roeder
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

Review 8.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

9.  EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer.

Authors:  Jennifer L Clancy; Michelle J Henderson; Amanda J Russell; David W Anderson; Ronaldo J Bova; Ian G Campbell; David Y H Choong; Graeme A Macdonald; Graham J Mann; Tania Nolan; Ged Brady; Olufunmilayo I Olopade; Erica Woollatt; Michael J Davies; Davendra Segara; Neville F Hacker; Susan M Henshall; Robert L Sutherland; Colin K W Watts
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

10.  Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Authors:  Georgios Giamas; Aleksandra Filipović; Jimmy Jacob; Walter Messier; Hua Zhang; Dongyun Yang; Wu Zhang; Belul Assefa Shifa; Andrew Photiou; Cathy Tralau-Stewart; Leandro Castellano; Andrew R Green; R Charles Coombes; Ian O Ellis; Simak Ali; Heinz-Josef Lenz; Justin Stebbing
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440

View more
  13 in total

1.  UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer.

Authors:  Bingbing Wu; Mei Song; Qun Dong; Gang Xiang; Jing Li; Xiaojing Ma; Fang Wei
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

2.  UBR5 is a novel regulator of WNK1 stability.

Authors:  Ji-Ung Jung; Anwesha B Ghosh; Svetlana Earnest; Staci L Deaton; Melanie H Cobb
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-20       Impact factor: 5.282

3.  Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Authors:  Lindsey S Treviño; Michael J Bolt; Sandra L Grimm; Dean P Edwards; Michael A Mancini; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2015-12-11

4.  Editor's Highlight: Analysis of the Effects of Cell Stress and Cytotoxicity on In Vitro Assay Activity Across a Diverse Chemical and Assay Space.

Authors:  Richard Judson; Keith Houck; Matt Martin; Ann M Richard; Thomas B Knudsen; Imran Shah; Stephen Little; John Wambaugh; R Woodrow Setzer; Parth Kothiya; Jimmy Phuong; Dayne Filer; Doris Smith; David Reif; Daniel Rotroff; Nicole Kleinstreuer; Nisha Sipes; Menghang Xia; Ruili Huang; Kevin Crofton; Russell S Thomas
Journal:  Toxicol Sci       Date:  2016-05-20       Impact factor: 4.849

Review 5.  Systems Medicine: The Application of Systems Biology Approaches for Modern Medical Research and Drug Development.

Authors:  Duncan Ayers; Philip J Day
Journal:  Mol Biol Int       Date:  2015-08-18

6.  Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.

Authors:  Cheng-Fei Jiang; Zhu-Mei Shi; Dong-Mei Li; Ying-Chen Qian; Yi Ren; Xiao-Ming Bai; Yun-Xia Xie; Lin Wang; Xin Ge; Wei-Tao Liu; Lin-Lin Zhen; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Mol Cancer       Date:  2018-04-23       Impact factor: 27.401

7.  High-throughput gene screen reveals modulators of nuclear shape.

Authors:  Andrew C Tamashunas; Vincent J Tocco; James Matthews; Qiao Zhang; Kalina R Atanasova; Lauren Paschall; Shreya Pathak; Ranjala Ratnayake; Andrew D Stephens; Hendrik Luesch; Jonathan D Licht; Tanmay P Lele
Journal:  Mol Biol Cell       Date:  2020-04-22       Impact factor: 4.138

8.  A genome-scale CRISPR-Cas9 screening method for protein stability reveals novel regulators of Cdc25A.

Authors:  Yuanzhong Wu; Liwen Zhou; Xin Wang; Jinping Lu; Ruhua Zhang; Xiaoting Liang; Li Wang; Wuguo Deng; Yi-Xin Zeng; Haojie Huang; Tiebang Kang
Journal:  Cell Discov       Date:  2016-05-24       Impact factor: 10.849

9.  Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells.

Authors:  Rui Chen; Jing Zhu; Yong Dong; Chao He; Xiaotong Hu
Journal:  Oncotarget       Date:  2015-10-20

Review 10.  Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Authors:  Haitao Yang; MariaLynn Jaeger; Averi Walker; Daniel Wei; Katie Leiker; Tao Weitao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.